Sign Up
Stories
Cancer Drug Approval Challenges
Share
Advancements in Cancer Treatment and Mar...
Cancer Drug Efficacy Concerns
Healthcare Innovations: Breakthroughs an...
ACTICOR BIOTECH Delays Key Documents
AI-Powered Raspberry Pi Stethoscope Inno...
ANJESO Drug Insight and Market Forecast
Overview
API
A study finds most cancer drugs granted accelerated approval lack significant benefits after five years. Meanwhile, Ribometrix introduces promising RNA-targeting strategies at AACR 2024.
Ask a question
How might the FDA's enhanced authority impact drug development and patient access?
What challenges do accelerated approval drugs face in transitioning to regular approval?
What potential implications do Ribometrix's RNA-targeting advancements hold for cancer treatment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Apr 2024
Coverage